FDA investigates the cancer risk of angiotensin-receptor blockers

07/15/2010 | Reuters

FDA officials are investigating angiotensin-receptor blockers, a class of blood pressure drugs, after clinical data suggested that they might increase the risk of cancer. However, the agency thinks "the benefits of ARBs continue to outweigh their potential risks."

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care